Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2018

01-07-2018 | Epidemiology

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Authors: Katherine Clifton, Angelica Gutierrez-Barrera, Junsheng Ma, Roland Bassett Jr., Jennifer Litton, Henry Kuerer, Stacy Moulder, Constance Albarracin, Gabriel Hortobagyi, Banu Arun

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Login to get access

Abstract

Purpose

As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported conflicting results in overall survival in patients receiving neoadjuvant or adjuvant systemic therapy. This study aims to analyze outcomes of adjuvant versus neoadjuvant in patients with early-stage triple-negative breast cancer with and without BRCA germline mutations.

Methods

Patients with stage I or II triple-negative breast cancer who had BRCA testing were identified from a prospective cohort study of 4027 patients. Clinical, demographic, genetic test results, chemotherapy, recurrence, and survival data were analyzed. Overall survival and disease-free survival were estimated using the Kaplan–Meier method.

Results

319 patients with stage I and II triple-negative breast cancer who met eligibility criteria were included in the analysis. 187 received adjuvant chemotherapy (58.6%) and 132 received neoadjuvant chemotherapy (41.4%). 135 were BRCA positive (42.3%) and 184 were BRCA negative (57.7%). There was no significant association between overall survival or disease-free survival and treatment with neoadjuvant versus adjuvant in the overall cohort. Furthermore, there were no significant differences between patient subgroups (neoadjuvant BRCA positive, neoadjuvant BRCA negative, adjuvant BRCA positive, and adjuvant BRCA negative) with respect to either overall survival or disease-free survival.

Conclusions

Neoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents.
Literature
1.
2.
Stover D, Bell CF, Tolaney SM (2016) Neoadjuvant and adjuvant chemotherapy considerations for triple negative breast cancer. Am J Hematol Oncol 12(3):6–12
3.
Hartman AR, Kaldate RR, Sailer LM et al (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787–2795CrossRefPubMed
4.
5.
Sharma P, Klemp JR, Kimler BF et al (2014) Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 145:707–714CrossRefPubMedPubMedCentral
6.
Greenup R, Buchanan A, Lorizio W et al (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20:3254–3258CrossRefPubMed
7.
Kwon JS, Gutierrez-Barrera AM, Young D et al (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28:4214–4220CrossRefPubMed
8.
Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. Monogr Natl Cancer Inst 30:96–102CrossRef
9.
Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785CrossRefPubMed
10.
Kennedy CR, Gao F, Margenthaler JA (2010) Neoadjuvant versus Adjuvant chemotherapy for triple negative breast cancer. J Surg Res 163(1):52–57CrossRefPubMed
11.
Fisher CS, Ma CX, Gillanders WE et al (2011) Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 19(1):253–258CrossRefPubMedPubMedCentral
12.
Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York
13.
Somlo G, Frankel PH, Arun BK et al (2017) Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California cancer consortium trial NCT01149083. Clin Cancer Res 23(15):4066–4076CrossRefPubMedPubMedCentral
14.
Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244CrossRefPubMed
15.
Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed
16.
Isakoff SJ, Puhalla S, Domchek SM et al (2017) A randomized phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol 13(4):307–320CrossRefPubMed
17.
Miller K, Tong Y, Jones D et al (2015) Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146. J Clin Oncol 33(15 suppl):1082
18.
19.
Tutt A, The TNT trial. Presented at 2014 San Antonio Breast Cancer Symposium, Dec 2014, San Antonio, TX
20.
Byrski T, Huzarski T, Dent R et al (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147(2):401–405CrossRefPubMed
21.
22.
Arun B, Bayraktar S, Liu DD et al (2011) Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 29(28):3739–3746CrossRefPubMedPubMedCentral
23.
O’Keefe DJ (2007) Brief report: post hoc power, observed power, a priori power, retrospective power, prospective power, achieved power: sorting out appropriate uses of statistical power analyses. Commun Methods Meas 1(4):291–299CrossRef
Metadata
Title
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
Authors
Katherine Clifton
Angelica Gutierrez-Barrera
Junsheng Ma
Roland Bassett Jr.
Jennifer Litton
Henry Kuerer
Stacy Moulder
Constance Albarracin
Gabriel Hortobagyi
Banu Arun
Publication date
01-07-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4727-9

Other articles of this Issue 1/2018

Breast Cancer Research and Treatment 1/2018 Go to the issue

Clinical trial

Acupuncture for breast cancer-related lymphedema: a randomized controlled trial

Clinical trial

Exercise and weight loss interventions and miRNA expression in women with breast cancer

Epidemiology

Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer

Rebuttal Letter

Cell-free DNA in breast cancer: a long way to go

Clinical trial

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients

Correction

Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits